Shares rose 3.7% after earnings, as Strata reported Q3 results ahead of its guidance and record free cash flow. Clinical services growth and earlier-than-planned logistics margin progress supported management’s outlook for 2027.
The stock gained 5.4% after reporting better-than-expected growth in the clinical business, driven by strong 23.8% sequential growth in Transplant Clinical revenue and expanding gross margins, which outweighed softness in the Logistics segment.
Strata’s shares rallied 10.8% following a quarter marked by robust revenue growth driven by Logistics and new Clinical business lines, alongside positive signs of improving cash flow and an active M&A pipeline that exceeded investor expectations.